HRCT Useful In Sclerodermal Lung Disease Treatment PDF Print E-mail
Thursday, 26 November 2009 10:46
In a recent Reuters Health article, it was reported that the serial scanning of the thorax with high-resolution computed tomography (HRCT) is useful for monitoring the response of Sclerodermal lung disease to therapy, according to a further report in the November Chest.

The report focused on 98 patients with sclerodermal-interstitial lung disease who had completed one year of treatment with either cyclophosphamide or placebo in a randomized Scleroderma Lung Study. According to senior author Dr. Donald P. Tashkin, from the University of California, the cyclophosphamide produced significant improvements in pulmonary function and symptoms. Dr. Tashkin, and his colleagues also compared parenchymal abnormalities between baseline and follow-up HRCT scans.

Amongst the 49 patients in the cyclophosphamide arm, 14 had worse fibrosis scores at 12 months and 35 had scores that were not worse. In contrast, among the 49 patients in the placebo group, 26 had worse fibrosis scores at 12 months and 23 had scores that were not worse.

HRCT fibrosis scores correlated with pulmonary function and skin thickness scores, the investigators said, and changes in dyspnea over time showed moderate correlations with changes in fibrosis.

"Our findings provide a rationale for performing follow-up HRCT scans in patients with scleroderma interstitial lung disease undergoing treatment with oral cyclophosphamide or some other potentially active agent as a means of assessing the patient's response to therapy and determining whether additional treatment is needed in patients with HRCT evidence of progressive fibrosis despite their existing therapy," Dr. Tashkin told Reuters Health.

"HRCT scans provide an objective method of assessing changes in both inflammation and fibrosis in the lungs of patients with interstitial lung disease," he added. "They therefore provide a useful complement to measured changes in lung physiology."

For a link to the full and original article, click here.
 
More articles :

» A Simple Blood Test Could Hold The Clue...

In a recent press release, the reported that a simple blood test could hold the clue and may even save lives. is a common condition, especially in teenagers, affecting approximately 10 million people in the UK. It can vary from being mild to very...

» The registry of the German Network for Systemic Scleroderma

N. Hunzelmann, E. Genth, T. Krieg, W. Lehmacher, I. Melchers, M. Meurer, P. Moinzadeh, U. Mu¨ ller-Ladner, C. Pfeiffer, G. Riemekasten, E. Schulze-Lohoff, C. Sunderkoetter, M. Weber, M. Worm, P. Klaus, A. Rubbert, K. Steinbrink, B. Grundt, R. Hein,...

» 5 Things to Know About Raynaud’s

Having a chronic condition like Raynaud’s requires vigilance. Here are five things that you should know about your condition from rheumatologists who treat it.Stay warm. Wear gloves and mittens and heavy socks whenever you expect to be in a cold...

» Rheumatic Autoimmune Diseases: A Local Perspective

Arguably one of the more exciting presentations delivered at the recently concluded , local Rheumatologist Dr. Haramnauth Dyaanand of the Gulf View Medical Centre, delved excitedly into the local context for autoimmune diseases. Starting off largely...

» Active Biotech Presents Data regarding the 57-57 Project at EULAR

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data from an exploratory clinical trial in Systemic Lupus Erythematosus (SLE) patients at the Annual European Congress of Rheumatology EULAR 2011, an international event for specialists in the...

» Scleroderma May Be Initated By Cancer

has reported that researchers at have discovered that some cases of are likely to have been initiated by Cancer.  In a landmark paper published in Science, researchers focusing on a select group of patients with both Scleroderma and Cancer,...